| scholarly article | Q13442814 |
| P356 | DOI | 10.1046/J.1365-2516.2003.00711.X |
| P698 | PubMed publication ID | 12558775 |
| P2093 | author name string | United Kingdom Haemophelia Centre Doctors' Organisation | |
| P2860 | cites work | Incidence of inhibitors in haemophilia A patients--a review of recent studies of recombinant and plasma-derived factor VIII concentrates | Q33709854 |
| Viral reduction techniques: types and purpose | Q34300869 | ||
| A new variant of Creutzfeldt-Jakob disease in the UK. | Q34374893 | ||
| Factor VIII and transmissible spongiform encephalopathy: the case for safety | Q34600710 | ||
| Continuous infusion of coagulation factors | Q34636862 | ||
| Factor XI deficiency and its management: Meeting at the Royal Free Hospital, London, 11 December 1995. | Q38841747 | ||
| Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs | Q43854615 | ||
| Transmission of BSE by blood transfusion in sheep | Q45186151 | ||
| Discrepancies in potency assessment of recombinant FVIII concentrates | Q45855093 | ||
| Influence of phospholipids on the assessment of factor VIII activity | Q45855102 | ||
| Continuous infusion of FVIII and FIX concentrates: in vitro analysis of clinically relevant parameters | Q45857733 | ||
| Transmission of hepatitis A to patients with hemophilia by factor VIII concentrates treated with organic solvent and detergent to inactivate viruses. The Italian Collaborative Group | Q45866115 | ||
| High responding factor VIII inhibitors in mild haemophilia - is there a link with recent changes in clinical practice? | Q45867049 | ||
| Eliminating parvovirus B19 from blood products | Q45870552 | ||
| Risks of immunodeficiency, AIDS, and death related to purity of factor VIII concentrate. Multicenter Hemophilia Cohort Study | Q45870728 | ||
| The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). | Q45872630 | ||
| In vitro factor VIII recovery during the delivery of ultrapure factor VIII concentrate by continuous infusion | Q45876148 | ||
| A survey of one-stage and chromogenic potencies in therapeutic factor VIII concentrates | Q45884580 | ||
| Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events | Q45885101 | ||
| The effect of monoclonal or ion-exchange purified factor VIII concentrate on HIV disease progression: a prospective cohort comparison | Q45888459 | ||
| Diagnosis of new variant Creutzfeldt-Jakob disease by tonsil biopsy | Q57093007 | ||
| P433 | issue | 1 | |
| P921 | main subject | hemophilia | Q134003 |
| P304 | page(s) | 1-23 | |
| P577 | publication date | 2003-01-01 | |
| P1433 | published in | Haemophilia | Q15753375 |
| P1476 | title | Guidelines on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders | |
| P478 | volume | 9 |
| Q83232969 | 7 Procoagulators |
| Q45868043 | A systematic approach to controlling problem bleeds in patients with severe congenital haemophilia A and high-titre inhibitors. |
| Q39648285 | A world-wide survey and field study in clinical haemostasis laboratories to evaluate FVIII:C activity assay variability of ADYNOVATE and OBIZUR in comparison with ADVATE. |
| Q45855778 | An open clinical study assessing the efficacy and safety of Factor IX Grifols, a high-purity Factor IX concentrate, in patients with severe haemophilia B. |
| Q36536149 | Anti-hemophilic factor (recombinant), plasma/albumin-free method (octocog-alpha; ADVATE) in the management of hemophilia A. |
| Q37303186 | Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A |
| Q36969491 | Blood product support for delivery in severe factor X deficiency: the use of thrombin generation to guide therapy |
| Q36374188 | Clinical perspectives of emerging pathogens in bleeding disorders. |
| Q36366931 | Congenital factor VII deficiency: therapy with recombinant activated factor VII -- a critical appraisal |
| Q38238972 | Current management of hemophilia B: recommendations, complications and emerging issues |
| Q45874455 | Efficient factor VIII affinity purification using a small synthetic ligand |
| Q53240284 | Experience with recombinant-activated factor VII in 30 patients with congenital factor VII deficiency. |
| Q24200171 | Fibrinogen concentrate in bleeding patients |
| Q58736865 | Haemophilia |
| Q37008132 | Haemophilia A: meeting the needs of individual patients |
| Q36221979 | Haemophilia B: Christmas disease |
| Q38040458 | Haemophilia B: current pharmacotherapy and future directions |
| Q35686292 | Haemophilia and the newborn |
| Q45213003 | Haemophilia part 1: an introduction |
| Q37912059 | Immune tolerance induction for patients with severe hemophilia A: a critical literature review |
| Q45880602 | In vitro comparison of the effect of two factor XI (FXI) concentrates on thrombin generation in major FXI deficiency |
| Q45863828 | Inhibitor development after switching of FVIII concentrate in multitransfused patients with severe haemophilia A. |
| Q50959861 | Long-term production of major coagulation factors and inhibitors by primary human hepatocytes in vitro: perspectives for clinical application. |
| Q83351532 | Menorrhagia: treatment options |
| Q36360330 | Octocog alfa, plasma/albumin-free method |
| Q37942603 | Operative management and outcomes in children with congenital bleeding disorders: a retrospective review at a single haemophilia treatment centre |
| Q48543476 | Pharmacokinetics of recombinant factor XIII at steady state in patients with congenital factor XIII A-subunit deficiency. |
| Q91944141 | Polysaccharide-based chromatographic adsorbents for virus purification and viral clearance |
| Q37062388 | Proteomics: applications in transfusion medicine. |
| Q24247217 | Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with Haemophilia A and inhibitors |
| Q24248625 | Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with Haemophilia A and inhibitors |
| Q24236388 | Recombinant Factor VIIa concentrate versus plasma derived concentrates for the treatment of acute bleeding episodes in people with haemophilia and inhibitors |
| Q36133808 | Recombinant factor VIIa (Eptacog Alfa): a review of its use in congenital or acquired haemophilia and other congenital bleeding disorders |
| Q37019077 | Recombinant factor VIIa (eptacog alfa): a pharmacoeconomic review of its use in haemophilia in patients with inhibitors to clotting factors VIII or IX. |
| Q24187069 | Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors |
| Q38743779 | Recombinant factor XIII prophylaxis is safe and effective in young children with congenital factor XIII-A deficiency: international phase 3b trial results. |
| Q38444981 | Recombinant proteins in therapeutics: haemophilia treatment as an example |
| Q37209117 | Recommendations for the transfusion of plasma and platelets |
| Q42096335 | Recommendations for the use of antithrombin concentrates and prothrombin complex concentrates |
| Q37062415 | Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma |
| Q45868033 | Reformulated BeneFix: efficacy and safety in previously treated patients with moderately severe to severe haemophilia B. |
| Q31129968 | Should prophylaxis be used in adolescent and adult patients with severe haemophilia? An European survey of practice and outcome data |
| Q37139733 | Sucrose-formulated octocog alfa: a review of its use in patients with haemophilia A. |
| Q45863628 | Switching between full-length and B-domain-deleted factor VIII and the risk of inhibitors |
| Q33959616 | Systemic AL amyloidosis with acquired factor X deficiency: A study of perioperative bleeding risk and treatment outcomes in 60 patients |
| Q38013763 | Tertiary prophylaxis in adults: is there a rationale? |
| Q36533439 | The obstetric and gynaecological management of women with inherited bleeding disorders--review with guidelines produced by a taskforce of UK Haemophilia Centre Doctors' Organization |
Search more.